# A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)

> **NCT01466647** · PHASE1 · COMPLETED · sponsor: **Axelar AB** · enrollment: 12 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** AXL1717

## Key facts

- **NCT ID:** NCT01466647
- **Lead sponsor:** Axelar AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466647, "A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01466647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*